← All trials
NCT05285891
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 16, 2022
- Primary completion
- Aug 1, 2028
- Completion date
- Aug 1, 2028
- First posted
- Mar 18, 2022
- Last posted
- Dec 20, 2022
- Enrollment
- 175
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)Lead sponsor
- GenentechCollaborator
- National Institute of Allergy and Infectious Diseases (NIAID)Collaborator
- University of PennsylvaniaStudy chair
- Rho, Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.